Jeffrey S. Parkin

Array ( [id] => 19497917 [patent_doc_number] => 20240336935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => SELF-INACTIVATING LENTIVIRAL VECTOR COMPRISING A FOXP3 EXPRESSION CASSETTE [patent_app_type] => utility [patent_app_number] => 18/754883 [patent_app_country] => US [patent_app_date] => 2024-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19122 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18754883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19724100 [patent_doc_number] => 20250026851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-23 [patent_title] => ADENOVIRUS ARMED WITH BISPECIFIC T CELL ACTIVATOR [patent_app_type] => utility [patent_app_number] => 18/744059 [patent_app_country] => US [patent_app_date] => 2024-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18744059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19570439 [patent_doc_number] => 20240374731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => IMMUNOGENIC TRIMERS [patent_app_type] => utility [patent_app_number] => 18/733214 [patent_app_country] => US [patent_app_date] => 2024-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33463 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18733214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19570439 [patent_doc_number] => 20240374731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => IMMUNOGENIC TRIMERS [patent_app_type] => utility [patent_app_number] => 18/733214 [patent_app_country] => US [patent_app_date] => 2024-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33463 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18733214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19497918 [patent_doc_number] => 20240336936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => METHODS AND CONSTRUCTS FOR PRODUCTION OF LENTIVIRAL VECTOR [patent_app_type] => utility [patent_app_number] => 18/680137 [patent_app_country] => US [patent_app_date] => 2024-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10975 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18680137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19904340 [patent_doc_number] => 12281336 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => Chikungunya virus (CHIKV) virus-like particles (VLPS) comprising the C, E1, and E2 structural proteins [patent_app_type] => utility [patent_app_number] => 18/675059 [patent_app_country] => US [patent_app_date] => 2024-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 118 [patent_figures_cnt] => 54 [patent_no_of_words] => 17240 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18675059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19916368 [patent_doc_number] => 12291726 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter [patent_app_type] => utility [patent_app_number] => 18/649467 [patent_app_country] => US [patent_app_date] => 2024-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6314 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18649467 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20385477 [patent_doc_number] => 12485187 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Method for improving retroviral transduction and gene editing in hematopoietic stem cells using clyclosporin H and UM171 [patent_app_type] => utility [patent_app_number] => 18/597488 [patent_app_country] => US [patent_app_date] => 2024-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 12 [patent_no_of_words] => 15549 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18597488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19570240 [patent_doc_number] => 20240374532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => METHODS AND MATERIALS FOR KILLING HIV INFECTED CELLS [patent_app_type] => utility [patent_app_number] => 18/444033 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9140 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18444033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417403 [patent_doc_number] => 20240293526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => EBOLAVIRUS AND MARBURGVIRUS VACCINES [patent_app_type] => utility [patent_app_number] => 18/427737 [patent_app_country] => US [patent_app_date] => 2024-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19316865 [patent_doc_number] => 20240238405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => METHODS OF ELICITING ANTIBODIES THAT BIND TO FULL-LENGTH GLYCOSYLATED HIV-1 ENV USING MULTIMERIZED ENV CORES [patent_app_type] => utility [patent_app_number] => 18/402480 [patent_app_country] => US [patent_app_date] => 2024-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28593 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18402480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19570418 [patent_doc_number] => 20240374710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => Vaccine Compositions For Preventing Coronavirus Disease [patent_app_type] => utility [patent_app_number] => 18/396370 [patent_app_country] => US [patent_app_date] => 2023-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42271 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18396370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20127949 [patent_doc_number] => 12370249 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus glycoprotein (GP) and matrix protein (VP40) [patent_app_type] => utility [patent_app_number] => 18/394555 [patent_app_country] => US [patent_app_date] => 2023-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 19 [patent_no_of_words] => 21194 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18394555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20127949 [patent_doc_number] => 12370249 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus glycoprotein (GP) and matrix protein (VP40) [patent_app_type] => utility [patent_app_number] => 18/394555 [patent_app_country] => US [patent_app_date] => 2023-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 19 [patent_no_of_words] => 21194 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18394555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528193 [patent_doc_number] => 20240352095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => ARENAVIRUS MONOCLONAL ANTIBODIES AND USES [patent_app_type] => utility [patent_app_number] => 18/392147 [patent_app_country] => US [patent_app_date] => 2023-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18392147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403644 [patent_doc_number] => 20240287155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => RNA REPLICON FOR EXPRESSING AT CELL RECEPTOR OR AN ARTIFICIAL T CELL RECEPTOR [patent_app_type] => utility [patent_app_number] => 18/538898 [patent_app_country] => US [patent_app_date] => 2023-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18538898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20212583 [patent_doc_number] => 12409217 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties [patent_app_type] => utility [patent_app_number] => 18/385250 [patent_app_country] => US [patent_app_date] => 2023-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 27 [patent_no_of_words] => 3427 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18385250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20212583 [patent_doc_number] => 12409217 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties [patent_app_type] => utility [patent_app_number] => 18/385250 [patent_app_country] => US [patent_app_date] => 2023-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 27 [patent_no_of_words] => 3427 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18385250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20212583 [patent_doc_number] => 12409217 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties [patent_app_type] => utility [patent_app_number] => 18/385250 [patent_app_country] => US [patent_app_date] => 2023-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 27 [patent_no_of_words] => 3427 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18385250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19915212 [patent_doc_number] => 12290558 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => SARS-CoV-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-ETSD immunogens [patent_app_type] => utility [patent_app_number] => 18/488629 [patent_app_country] => US [patent_app_date] => 2023-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 28 [patent_no_of_words] => 16212 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18488629 [rel_patent_id] =>[rel_patent_doc_number] =>)